Authors: Sharon Salt, Editor
Today (30 May) marks World Multiple Sclerosis (MS) Day: an annual opportunity to raise awareness of MS and to work together as a global community to find ways to improve the lives of those with MS. We wanted to use this opportunity to mark some of the recent research and developments in the field over the course of the year so far.
This year’s theme for the international campaign is #BringingUsCloser – you can find out more about how MS research is bringing us closer to ending MS by following the hashtag on Twitter:
#WorldMSDay! This year’s #bringinguscloser campaign celebrates how #MSResearch is bringing us closer to ending #MS. It’s an opportunity to join together in solidarity to raise awareness, improve quality of life with MS and work together to end MS! http://bit.ly/2EW5Fjj
— World MS Day (@WorldMSDay) 30 May 2018
Did you know that multiple sclerosis was first defined in 1868? 150 years later and we are closer to understanding it but still a long way to go to cure it. That’s why local treatment & support is still so important.
#worldMSday #bringinguscloser #chilternsmscentre
— Chilterns MS Centre (@ChilternsMS) 30 May 2018
Have you been faced with tough decisions about
#MS treatments? Having access to accurate, trustworthy information can make all the difference. Great video from @mssocietyuk for #WorldMSDay, featuring people with MS talking about difficult treatment choices. #bringinguscloser
— World MS Day (@WorldMSDay) 30 May 2018
— Saolta Group (@saoltagroup) 30 May 2018
The year so far in MS research
Stem cell trial
Our most read article in the field so far features, ‘Stem cell transplant could be ‘game changer’ for MS patients’. Where earlier last month, an international trial (MIST) revealed that hematopoietic stem cell transplantation was an effective and safe treatment option for patients with relapsing MS. The researchers concluded that hematopoietic stem cell transplantation was statistically superior to continued disease-modifying therapies in patients with relapsing–remitting MS with ≥2 relapses a year.
We’ve also seen a large number of industry news being featured around MS, with an announcement in March that siponimod could improve outcome in patients with secondary progressive MS. Almost 1 month later, results from the EXPAND study of oral siponimod were announced, revealing that Novartis was filing for regulatory approval with the US FDA. Furthermore, towards the end of April, additional Phase III data for siponimod were announced once again.
The highlights above are only a select few of all the fantastic research that has happened so far in the research field – we’ve also compiled all our exclusive content on MS in the year so far, below:
Further headlines from 2018
- Multiple sclerosis: new UK guidelines on disease-modifying therapies
- First disease-modifying therapy approved for pediatric multiple sclerosis
- AAN 2018: Additional biomarker and vaccine responses announced for ocrelizumab in multiple sclerosis
- Can living in a sunnier climate in your youth reduce the risk of MS?
- Ozanimod receives refusal-to-file for relapsing multiple sclerosis
- FDA grants delayed approval for relapsing MS drug, Glatopa®
- Ocrelizumab approved for treatment of primary progressive multiple sclerosis
- NCTalks with Jens Kuhle: monitoring multiple sclerosis using blood neurofilament light protein
- NCTalks with Robert Fox: current landscape and potential treatment regimens for ibudilast in multiple sclerosis
- NCTalks with Alexander Rae-Grant: A new guideline for multiple sclerosis treatment
Future project on multiple sclerosis
Finally, we’re delighted to announce a future project that we’re currently working on, entitled: ‘Ask the Experts: emerging therapies in multiple sclerosis’. We’re hoping to get this feature published in June for you, so be sure to stay tuned to Neuro Central to find out more about this.
We hope that you’ve enjoyed our selection of content from the year so far. We’re very much looking forward to continuing to bring updates from across the field to those researching, living with and fighting MS.
My very best wishes,
Editor, Neuro Central
Like what you see? Become a member FREE of charge for full access to all features, as well as complimentary access to our five partnered journals: Future Neurology, Neurodegenerative Disease Management, Pain Management, CNS Oncology and the open access journal Concussion.